stockportfolio.pro
Nurix Therapeutics, Inc. (NRIX)
Healthcare · Biotechnology · NasdaqGM
Nurix Therapeutics, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $31.11M | $17.82M | $29.75M | $38.63M | $76.99M | $54.55M | $83.98M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-21.70M | $-43.24M | $-117.19M | $-180.36M | $-143.95M | $-193.57M | $-264.46M |
| Net margin | -69.7% | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
Source: Nurix Therapeutics, Inc. SEC filings (10-K).
Explore 7 years of Nurix Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NRIX in your portfolio →
Nurix Therapeutics, Inc. financial history by metric
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Nurix Therapeutics, Inc. — frequently asked questions
What is Nurix Therapeutics, Inc.'s revenue?
Nurix Therapeutics, Inc. (NRIX) reported revenue of $83.98M for fiscal year 2025, up 54.0% from the prior year, according to its SEC filings.
Is Nurix Therapeutics, Inc. profitable?
No — NRIX reported a net loss of $-264.46M in fiscal 2025.
What is NRIX's P/E ratio?
Nurix Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Nurix Therapeutics, Inc. growing?
NRIX's revenue grew at roughly 36.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Nurix Therapeutics, Inc. have?
As of fiscal year 2025, NRIX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Nurix Therapeutics, Inc.'s market cap?
Nurix Therapeutics, Inc. (NRIX) has a market capitalization of about $1.74B, based on the latest data in our nightly-refreshed cache.
When does Nurix Therapeutics, Inc.'s fiscal year end?
NRIX's fiscal year ends in November. Its most recent annual filing covers the fiscal year ending 2025-11-30.
Where does this data come from?
All figures are computed from Nurix Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.